4 charts show why Moderna vaccine recipients may not need boosters as much as people who got Pfizer's vaccine

Emerging patterns suggest Moderna's two-dose vaccine might have a slight edge over Pfizer's in the long run.
24/7 Wall St

Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Moderna (MRNA) has surged 94% in 2026 so far, crushing Pfizer (PFE) at just +4% and beating Novavax (NVAX) at +41%, as Moderna's leadership restructuring has signaled a 2027-2028 product launch push.
AOL

Pfizer vs Moderna: Which Pharma Stock Has More Upside?

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were both leaders in the coronavirus vaccine market. However, as sales of these products have declined significantly in recent years -- due to the ...
24/7 Wall St

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has ...
AOL

Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. Today's catalyst is ...